Researchers have successfully rejuvenated aging liver cells in a preclinical study, using both mouse models and human cell cultures. The team pinpointed ferroptosis, an iron-dependent form of cell death, as a key driver of age-related degeneration in hepatocytes—the liver’s primary functional cells. They discovered that older livers and those affected by non-alcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction–associated steatotic liver disease (MASLD), exhibit elevated gene expression associated with ferroptotic cell death.
To test whether this process could be reversed, researchers induced MASLD in both young (3‑month) and old (24‑month) mice via a high-fat diet. The older mice received injections of Ferrostatin‑1, a chemical inhibitor of ferroptosis, while continuing the disease-inducing diet. Remarkably, liver tissue from treated older mice resembled that of much younger mice, both in appearance and in gene expression profiles. Senior author Dr. Anna Mae Diehl of Duke University described the outcome as making “old mice eating hamburgers and fries” regrow “livers like those of young teenagers eating hamburgers and fries.”
Implications for Human Liver Health
This study has significant implications for human liver disease, particularly MASLD—a condition that affects roughly one in three adults globally and poses risks of cirrhosis and liver failure. The researchers found the same ferroptosis-associated genes elevated in liver tissue from obese human patients with MASLD, suggesting clinical relevance. Acknowledging the broader potential of targeting ferroptosis, scientists assert that similar mechanisms may underlie age-related degeneration in organs such as the heart, kidneys, and pancreas.
Ferroptosis as a Therapeutic Target
Ferroptosis results from iron- and lipid-driven destructive cascades within cells, and pharmacologically blocking this pathway represents a novel route to reverse cellular aging in the liver. Though Ferrostatin‑1 is a research tool—not yet approved for clinical use—the findings open the door for drug development aimed at protecting aging tissues. As one expert noted, inhibiting ferroptosis may mitigate aging-related injury in organs but requires caution due to potential dual roles in health and disease.
From Bench to Bedside?
Published in Nature Aging, this research highlights the liver’s surprising capacity for rejuvenation—even among aged individuals—by targeting specific cellular death pathways. Though moving from mouse models to human treatments involves significant challenges, the clear identification of therapeutic gene targets and initial human tissue validation put the initiative on a promising translational track. As Dr. Diehl stated, “aging is at least partially reversible”—a hopeful message for future therapies against age-associated liver disease.
Visit the Health & Wellness category for more.